Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07583030 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

StatusWithdrawn
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Withdrawn before enrolling Sponsor's reason: pipeline strategy change Enrollment target: estimated 44 to confirmed 0 · Start date changed from estimate of Apr 20, 2026 to Sep 23, 2026 · Primary completion date changed from estimate of Sep 20, 2028 to Sep 23, 2026 · 3 more Show 6 more changesShow less
    • Enrollment target: estimated 44 to confirmed 0
    • Start date changed from estimate of Apr 20, 2026 to Sep 23, 2026
    • Primary completion date changed from estimate of Sep 20, 2028 to Sep 23, 2026
    • Study sites: 5 to 4
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 5 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
Trial Details
NCT Number NCT07583030
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Nanjing Legend Biotech Co.
Conditions Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov